# 重磅！显著延长肺癌患者总生存期：泰瑞沙（奥希替尼）一线治疗临床试验最新结果公布

EGFR阳性肺癌在亚洲高发

[1] TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer. Retrieved August 12, 2019, from https://www.businesswire.com/news/home/20190809005184/en

[2] Wu, et al. (2019). Ann Oncol, https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Pan-Asian-adapted-ESMO-Clinical-Practice-Guidelines-for-the-management-of-patients-with-metastatic-non-small-cell-lung-cancer

[3] NCCN Guidelines Version 5.2019: Non-Small Cell Lung Cancer, from https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

[4] ASCO. Retrieved August 12, 2019, from https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/understanding-targeted-therapy

“癌症之王”，哪些人适合做早期筛查，哪些人不适合做？

“走下神坛”的阿司匹林，还能用来预防癌症吗？